Radionetics Oncology

Radionetics Oncology is a pioneering pharmaceutical company dedicated to discovering and developing novel radiotherapeutics for the treatment of various oncology indications. The company's platform technology utilizes nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a wide array of cancers by selectively binding to peptide receptors expressed on these tumors. This innovative nonpeptide technology effectively addresses the prevailing challenges in peptide and protein targeted radiotherapeutics, especially in terms of optimizing drug-like characteristics and manufacturing. With a focus on rapidly advancing a pipeline of drug candidates to treat a broad range of cancers, Radionetics Oncology is also engaging in drug discovery efforts in collaboration with Crinetics Pharmaceuticals to identify drug candidates for additional receptor targets. Founded in 2021 and headquartered in the United States, the company recently secured a substantial $52.50M Series A investment on 03 January 2024 from notable investors including DCVC, 5AM Ventures, GordonMD Global Investments, Crinetics Pharmaceuticals, and Frazier Life Sciences. This significant investment is a testament to the company's potential and the promise of its innovative approach to cancer treatment.